Form 4: Precision BioSciences GC Sells Shares After RSU Vesting

Precision BioSciences' General Counsel, Dario Scimeca, sold 4,925 shares of common stock to cover tax obligations following the vesting of 16,667 Restricted Stock Units.

Summary

• Dario Scimeca, General Counsel and Secretary of Precision BioSciences Inc. (DTIL), reported transactions involving company stock.
• On February 17, 2026, 16,667 Restricted Stock Units (RSUs) vested, representing a contingent right to receive an equal number of common shares.
• Following the RSU vesting, Scimeca beneficially owned 61,382 shares of common stock.
• On February 18, 2026, Scimeca sold 4,925 shares of common stock at a price of $3.84 per share.
• The sale was executed under a Rule 10b5-1 plan adopted on September 29, 2025, specifically as a 'sell-to-cover' transaction to satisfy tax withholding obligations related to the RSU vesting.
• After these transactions, Scimeca beneficially owns 56,457 shares of common stock and 33,333 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While an insider sale reduces direct ownership, the context of RSU vesting and a pre-planned 'sell-to-cover' for tax purposes is routine and expected, reflecting ongoing executive compensation rather than a negative outlook.

Positives

• The vesting of 16,667 Restricted Stock Units (RSUs) indicates continued service and compensation for a key executive.
• The transaction was pre-planned under a Rule 10b5-1 plan, suggesting a structured approach to managing equity compensation and tax liabilities.

Negatives

• A sale of 4,925 shares by an insider, even for tax purposes, reduces their direct ownership stake in the company.

Future Outlook

The remaining Restricted Stock Units (RSUs) are scheduled to vest in three substantially equal annual installments beginning on February 17, 2026, contingent on the reporting person's continued service to the Issuer.

Management Comments

• The sales were effected pursuant to a Rule 10b5-1 plan adopted on September 29, 2025.
• The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions, particularly those involving RSU vesting and subsequent 'sell-to-cover' sales, are routine occurrences in publicly traded companies. These transactions are generally not indicative of a change in management's outlook on the company's prospects, especially when conducted under a pre-arranged 10b5-1 plan, which is designed to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: The sale of shares by an insider, even for tax purposes, slightly dilutes the overall ownership structure but is a common and expected event for equity-compensated executives. The pre-planned nature under a 10b5-1 plan mitigates concerns about opportunistic selling.
• Employees: The vesting of RSUs for a key executive reinforces the company's compensation structure and retention strategy for its leadership.

Next Steps

• Remaining Restricted Stock Units (RSUs) are scheduled to vest in substantially equal annual installments beginning February 17, 2026, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving RSU vesting and a 'sell-to-cover' for tax obligations, executed under a pre-established 10b5-1 plan. Such transactions are common and generally do not provide new material information to warrant a change in investment thesis. The filing itself does not offer sufficient data to recommend a 'buy' or 'sell' action, thus a 'hold' recommendation is appropriate, maintaining existing positions while awaiting more substantive corporate news or financial results.

Keywords

Precision BioSciences, DTIL, Dario Scimeca, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Sell-to-Cover, 10b5-1 Plan, Common Stock